112159-16-7

Usage

Uses

Used in Pharmaceutical Industry:
Boc-L-methionine is used as a building block in peptide synthesis for the production of various drugs and medications. Its protective Boc group allows for the controlled assembly of complex peptide structures, facilitating the development of novel therapeutic agents.
Used in Research and Development:
In the realm of research and development, Boc-L-methionine serves as a key component in the synthesis of peptides and proteins. Its protective properties enable scientists to explore the structure and function of these biomolecules, leading to advancements in our understanding of biological processes and the discovery of new therapeutic targets.
Used in Biochemistry and Biotechnology:
Boc-L-methionine is employed as a valuable tool in biochemistry and biotechnology, where its ability to protect the amino group of methionine is crucial for the synthesis of modified peptides and proteins with specific functions. This allows for the development of innovative applications in areas such as drug design, diagnostics, and therapeutics.

Upstream product

• 6461-04-7 (R)-2-amino-5-methoxy-5-oxopentanoic acid 
• 34619-03-9 tert-butyldicarbonate 
• 6893-26-1 D-Glutamic acid 
• 1499-55-4 DL-glutamic acid-5-methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 617-65-2 Glutamic acid 
• 187458-77-1 glutamic acid diester hydrochloride 
• 27025-22-5 D-glutamic acid-5-methyl ester; hydrochloride 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 

Downstream Products

• 96014-24-3 (R)-4-Amino-4,5-dihydro-furan-2-carboxylic acid 
• 76379-02-7 t-butoxycarbonyl-D-glutamic acid γ-methyl ester dicyclohexylamine salt 
• 1323407-86-8 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 
• 1323405-59-9 3-(4-((4-((4-methylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 132245-78-4 1-benzyl-5-methyl-2-((tert-butyloxycarbonyl)amino)pentanedioate 
• 1200838-12-5 4-tert-Butoxycarbonylamino-5-(toluene-4-sulfonyloxy)-pentanoic acid methyl ester 
• 138847-43-5 5-[(2-Benzylsulfanyl-ethyl)-methyl-amino]-4-[2-(1-ethoxy-ethylsulfanyl)-acetylamino]-pentanoic acid methyl ester 
• 138847-44-6 5-[(2-Benzylsulfanyl-ethyl)-methyl-amino]-4-[2-(1-ethoxy-ethylsulfanyl)-acetylamino]-pentanoic acid 

Relevant academic research and scientific papers

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.

ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3e (CD3) provided herein, in treating, preventing or managing multiple myeloma.

METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in?vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.

Inhibition of glyoxalase I: The first low-nanomolar tight-binding inhibitors

A series of rational modifications to the structure of known S-(N-aryl-N-hydroxycarbamoyl)glutathione-based glyoxalase I inhibitors culminated in the discovery of the first single-digit nanomolar inhibitor. This study makes available key information about possible means to address the issues of metabolic instability, low potency, and synthetic complexicity that have plagued the area of glyoxalase I inhibition. Knowledge garnered from this study has implications in the design of inhibitors with higher conformational definition and lower peptidic character.

Synthesis of enantiomerically pure β- and γ-amino acids from aspartic and glutamic acid derivatives

An efficient synthesis of enantiomerically pure β- and γ-amino acids starting from commercially available aspartic and glutamic acid derivatives is described. The acid function, α to the amino group, is first transformed to a good leaving group and the pr

Glucosamine peptide derivatives, their production and use

Novel glucosamine-peptide derivatives of the formula: STR1 wherein m is 0 or 1; n is 0 or an integer of 1 to 9; R is lower alkyl which may be substituted with hydroxyl, or aryl; R1 is hydrogen or acyl having an acyclic hydrocarbon group, the terminal of which may be substituted with a cyclic hydrocarbon group directly, via a carbonyl group or via an oxygen atom; provided that when R1 is hydrogen m is 1; R2 is hydrogen or lower alkyl which may form a ring by connecting its terminal with the α-nitrogen atom when n is 0, or hydrogen when n is an integer of 1 to 9; R3 is hydrogen or lower alkyl; R4 and R5 are each hydrogen or lower alkyl which may be substituted with hydroxyl or benzyloxyl; R6 is hydrogen or lower alkyl; R7 is alkyl which may be substituted with lower alkoxyl or aralkyl; R8 and R9 are each hydrogen, lower alkyl or aralkyl; and (D) and (L) each indicate configurations if their respective carbon atoms are asymmetric; or an acid addition salt thereof, have immunostimulatory activity.